Hepatic risks of chemoprophylaxis
Reference | N | Hepatitis/100000* | % Completion | Comments |
Regimen 6H | ||||
IUALTD2 | 6965 | 480 | 78 | 65% protective efficacy (one death from 6H) |
Jasmer3 | 282 | 1000 | 59 | |
Nolan4 | 11141 | 100 | – | Female OR 3.3 (95% CI 0.87 to 12.45) White OR 2.60 (95% CI 0.75 to 8.95) Increase with age χ2 5.22 (p=0.02) |
Bailey5 | 427 | 1170 | ||
Weighted average | 18815 | 278 | ||
Regimen 3RH | ||||
HK TB Service6 | 170 | 1766 | – | 50% protective efficacy in silicosis |
Regimen 4-6R | ||||
Menzies7 | 418 | 717 | 78 | |
Regimen 2RZ | ||||
Lee8 | 148 | 9459 | 57 | Female OR 4.1 (95% CI 1.2 to 14.3) Recent conversion OR 14.3 (95% CI 1.8 to 115) |
Jasmer3 | 307 | 7700 | 61 | Age >35 OR 12.2 (95% CI 1.49 to 100.3) OR 8.46 × isoniazid (95% CI 1.9 to 76.5) |
Stout9 | 114 | 5300 | 67.5 | |
Weighted average | 569 | 6648 |
Adapted from reference 10 with permission.
↵* Symptomatic or grade 3/4 hepatitis.
H, isoniazid; R, rifampicin; Z, pyrazinamide.